Related Experiment Video
Updated: Feb 18, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative Stress and Inflammation in Rats
Nawal M Al-Rasheed1,2, Nouf M Al-Rasheed1, Iman H Hasan1
1Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Insights
Simvastatin treatment improved body weight and reduced hyperglycemia in diabetic rats with cardiomyopathy. The study found simvastatin alleviates diabetic cardiomyopathy by reducing oxidative stress, inflammation, and apoptosis.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Diabetic cardiomyopathy (DCM) is a cardiac complication of diabetes.
- Hyperglycemia-induced oxidative stress and inflammation contribute to DCM pathogenesis.
Purpose of the Study:
- To investigate the protective effects of simvastatin on experimental diabetic cardiomyopathy.
- To elucidate the mechanisms underlying simvastatin's action in DCM.
Main Methods:
- Diabetes was induced in rats using streptozotocin.
- Rats received simvastatin treatment for 90 days.
- Cardiac function, oxidative stress markers, inflammatory mediators, and apoptosis were assessed.
Main Results:
- Simvastatin improved body weight, attenuated hyperglycemia, and reduced cardiac hypertrophy in diabetic rats.
- Simvastatin decreased cardiac injury markers (CK-MB, troponin I), lipid peroxidation, and inflammation (NF-κB).
- Simvastatin reversed decreased antioxidant defenses and reduced cardiac caspase-3 activity.
Conclusions:
- Simvastatin effectively alleviates experimental diabetic cardiomyopathy.
- The cardioprotective effects are attributed to the attenuation of oxidative stress, inflammation, and apoptosis.
Abstract:
Simvastatin is a lipid-lowering agent used to treat hypercholesterolemia and to reduce the risk of heart disease. This study scrutinized the beneficial effects of simvastatin on experimental diabetic cardiomyopathy (DCM), pointing to the role of hyperglycemia-induced oxidative stress and inflammation. Diabetes was induced by intraperitoneal injection of streptozotocin and both control and diabetic rats received simvastatin for 90 days. Diabetic rats showed significant cardiac hypertrophy, body weight loss, hyperglycemia, and hyperlipidemia. Serum creatine kinase MB (CK-MB) and troponin I showed a significant increase in diabetic rats. Simvastatin significantly improved body weight, attenuated hyperglycemia and hyperlipidemia, and ameliorated CK-MB and troponin I. Simvastatin prevented histological alterations and deposition of collagen in the heart of diabetic animals. Lipid peroxidation and nitric oxide were increased in the heart of diabetic rats whereas antioxidant defenses were decreased. These alterations were significantly reversed by simvastatin. In addition, simvastatin decreased serum inflammatory mediators and expression of NF-κB in the diabetic heart. Cardiac caspase-3 was increased in the diabetic heart and decreased following treatment with simvastatin. In conclusion, our results suggest that simvastatin alleviates DCM by attenuating hyperglycemia/hyperlipidemia-induced oxidative stress, inflammation, and apoptosis.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cardiomyopathy V: Interprofessional Care
Coronary Artery Disease I: Introduction

